13:40 , Apr 13, 2018 |  BC Week In Review  |  Company News

Novartis to acquire AveXis for $8.7B

Novartis AG (NYSE:NVS; SIX:NOVN) is acquiring gene therapy company AveXis Inc. (NASDAQ:AVXS) for $218 per share, or about $8.7 billion. The price represents an 88% premium to AveXis' close of $115.91 on April 6, before...
19:43 , Apr 9, 2018 |  BC Extra  |  Company News

Novartis to acquire AveXis for $8.7B

Novartis AG (NYSE:NVS; SIX:NOVN) is acquiring gene therapy company AveXis Inc. (NASDAQ:AVXS) for $218 per share, or about $8.7 billion. The price represents an 88% premium to AveXis' close of $115.91 on Friday, before the...
07:00 , Jun 15, 2015 |  BioCentury  |  Emerging Company Profile

Freshening the gene pool

Horama S.A.S. is developing two gene therapies that target mutations no other companies are working on as a way of differentiating itself from the growing fraternity of ophthalmic gene therapy companies. The company was founded...